BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, will present the results of two transformative studies at the Society for Neuroscience Annual Meeting, Neuroscience 2024. The conference will take place from October 5-9, 2024, in Chicago, Illinois.

波士顿--（商业新闻短讯）--BPGbio，Inc.，一家领先的生物学第一，人工智能驱动的临床阶段生物制药公司，专注于线粒体生物学和蛋白质稳态，将在神经科学学会2024年年会上介绍两项变革性研究的结果。会议将于2024年10月5日至9日在伊利诺伊州芝加哥举行。

Both studies leveraged BPGbio’s proprietary NAi Interrogative Biology® Platform, which employs a hypothesis-free, biology-first approach to drug and diagnostics discovery..

这两项研究都利用了BPGbio专有的NAi Questive Biology®平台，该平台采用无假设，生物学优先的方法进行药物和诊断发现。。

In the first study, titled “Disruption of Mutant, PolyQ Expanded Huntingtin Aggregation by Modulation of UBE2K, a Novel Ubiquitin-Proteasome Drug Target,” researchers showed that reduction of the E2 ubiquitin-conjugating enzyme, UBE2K/HIP2, leads to a loss of mutant Htt aggregates, which cause Huntington’s Disease.

在第一项题为“突变的破坏，PolyQ通过调节UBE2K（一种新型泛素-蛋白酶体药物靶标）来扩展亨廷顿蛋白聚集”的研究中，研究人员表明，E2泛素结合酶UBE2K/HIP2的减少会导致突变Htt聚集体的丢失，从而导致亨廷顿舞蹈病。

Researchers also demonstrated that treatment with the UBE2K discharge inhibitor, BPG-0812, a small molecule drug candidate, slowed the discharge of ubiquitin from UBE2K. The results of this study suggest that modulating UBE2K activity can effectively disrupt the aggregation of mutant Htt, presenting a promising new pathway for therapeutic intervention for Huntington’s Disease..

研究人员还证明，用UBE2K放电抑制剂BPG-0812（一种小分子候选药物）治疗可以减缓UBE2K中泛素的释放。这项研究的结果表明，调节UBE2K活性可以有效破坏突变Htt的聚集，为亨廷顿舞蹈病的治疗干预提供了一条有前景的新途径。。

The second-first study, titled “A Systems Biology Approach for Biomarker Discovery in Alzheimer’s Disease Using Multi-Omics and Bayesian Artificial Intelligence,” identified several novel liver and immune system protein biomarkers linked to cognitive decline. Notably, one biomarker can predict the time until cognitive decline in patients with Alzheimer’s Disease.

第二项第一项研究题为“使用多组学和贝叶斯人工智能在阿尔茨海默病中发现生物标志物的系统生物学方法”，确定了几种与认知能力下降有关的新型肝脏和免疫系统蛋白质生物标志物。值得注意的是，一种生物标志物可以预测阿尔茨海默病患者认知能力下降的时间。

These biomarkers were discovered through an analysis of plasma and buffy coat samples from participants in the Massachusetts Alzheimer Disease Research Center’s longitudinal study, in collaboration with Harvard Medical School. The findings, drawn from individuals with varying levels of cognitive impairment, highlight how liver and immune system dysfunction contribute to cognitive decline, offering significant potential for diagnosing and monitoring the progression of Alzheimer’s Disease..

这些生物标志物是通过与哈佛医学院合作，对马萨诸塞州阿尔茨海默病研究中心纵向研究参与者的血浆和血沉棕黄层样本进行分析而发现的。这些发现来自不同程度认知障碍的个体，突出了肝脏和免疫系统功能障碍如何导致认知能力下降，为诊断和监测阿尔茨海默病的进展提供了巨大的潜力。。

“Rare and age-related neurodegenerative diseases like Huntington’s Disease and Alzheimer’s Disease represent a significant healthcare and economic burden to society for decades to come. These findings highlight the power of our NAi Interrogative Biology platform in discovering disease modifying therapeutic targets and early-disease biomarkers that could one day transform the lives of people with neurodegenerative diseases,” said Niven R Narain, Ph.D., President and CEO of BPGbio.“Our research suggests new avenues and possibilities for the diagnosis of Alzheimer’s Disease, as well as for the treatment of Huntington’s Disease, both of which have patient populations in dire need of new solutions.”.

BPGbio总裁兼首席执行官Niven R Narain博士说：“亨廷顿舞蹈病和阿尔茨海默病等罕见且与年龄相关的神经退行性疾病代表了未来几十年社会的重大医疗保健和经济负担。这些发现突显了我们的NAi询问生物学平台在发现疾病修饰治疗靶点和早期疾病生物标志物方面的力量，这些标志物有朝一日可能会改变神经退行性疾病患者的生活。”我们的研究为阿尔茨海默病的诊断以及亨廷顿舞蹈病的治疗提供了新的途径和可能性，这两种疾病的患者群体都迫切需要新的解决方案。”。

Eric Nestler, M.D. Ph.D., Nash Family Professor of Neuroscience, Director, The Friedman Brain Institute, and Dean for Academic and Scientific Affairs of Icahn School of Medicine at Mount Sinai, and BPGbio Scientific Advisory Board Member and former President of the Society for Neuroscience, commented: “The ability to uncover novel drug targets and biomarkers using advanced AI-driven platforms like BPGbio's NAi Interrogative Biology platform is transformative for the field of neuroscience.

Eric Nestler，医学博士，纳什家族神经科学教授，弗里德曼大脑研究所所长，西奈山伊坎医学院学术和科学事务院长，BPGbio科学顾问委员会成员兼神经科学学会前主席，评论道：“使用先进的人工智能驱动平台（如BPGbio的NAi询问生物学平台）发现新型药物靶标和生物标志物的能力对神经科学领域具有变革性。

These findings not only deepen our understanding of complex diseases like Alzheimer's Disease and Huntington's Disease, but also pave the way for more precise therapeutic interventions, which are critical in addressing the profound unmet needs of these vulnerable populations.”.

这些发现不仅加深了我们对阿尔茨海默氏病和亨廷顿舞蹈病等复杂疾病的理解，而且为更精确的治疗干预铺平了道路，这对于解决这些弱势人群的深刻未满足需求至关重要。”。

Poster Presentation Details:

海报展示细节：

Title: A Systems Biology Approach for Biomarker Discovery in Alzheimer’s Disease Using Multi-Omics and Bayesian Artificial Intelligence

标题：使用多组学和贝叶斯人工智能发现阿尔茨海默病生物标志物的系统生物学方法

Date and Time: Monday, October 7, 2024, 1:00 - 2:00 p.m. CDT

日期和时间：2024年10月7日星期一，CDT下午1:00-2:00

Location: MCP Hall A

地点：MCP A厅

Presenter: Michael Kiebish, Ph.D.

由Michael Kiebish博士提出。

Program Number: PSTR207.21

程序编号：PSTR207.21

Title: Disruption of Mutant, PolyQ Expanded Huntingtin Aggregation by Modulation of UBE2K, a Novel Ubiquitin-Proteasome Drug Target

标题：通过调节新型泛素-蛋白酶体药物靶标UBE2K，破坏突变体PolyQ扩展了亨廷顿蛋白的聚集

Date and Time: Wednesday, October 9, 2024, 8:00 - 9:00 a.m. CDT

日期和时间：2024年10月9日星期三，CDT上午8:00-9:00

Location: MCP Hall A

地点：MCP A厅

Presenter: Gali Maor, Ph.D.

出席者：Gali Maor博士。

Program Number: PSTR394.09

课程编号：PSTR394.09

About BPGbio

关于BPGbio

BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world.

BPGbio是领先的生物学第一个AI支持的临床阶段生物制药，专注于线粒体生物学和蛋白质稳态。该公司拥有大量人工智能开发的治疗方法，涵盖肿瘤学，罕见病和神经病学，包括一些晚期临床试验。BPGbio的新方法得到了NAi的支持，NAi是其专有的询问生物学平台，受400多项美国和国际专利保护；世界上最大的临床注释非政府生物库之一，具有纵向样本；并独家访问世界上最强大的超级计算机。

With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease.

有了这些工具，BPGbio正在重新定义如何使用专门为解决大规模生物学挑战而设计的定制贝叶斯AI对患者生物学进行建模。该公司总部位于大波士顿，处于医学新时代的前沿，将生物学、多模式数据和人工智能相结合，改变我们理解、诊断和治疗疾病的方式。

For more information, visit www.bpgbio.com..

有关更多信息，请访问www.bpgbio.com。。